This clinical trial focuses on studying a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL). The study involves a treatment known as CD19-directed CAR T-cell therapy, which is a specialized treatment that uses the patient’s own immune cells to fight cancer. The trial will use a medication called 89Zr-atezolizumab, which is a form of the drug Tecentriq, to help visualize certain proteins in the body through imaging techniques.
The purpose of the study is to explore how a protein called PD-L1 is expressed in both normal tissues and cancerous areas before patients receive CAR T-cell therapy. This will be done using a special imaging method called PET/CT scan, which combines two types of scans to provide detailed pictures of the inside of the body. The study aims to see if the amount of 89Zr-atezolizumab taken up by the body can help distinguish between active cancer and other treatment-related changes.
Participants in the study will undergo PET/CT imaging before and after receiving CAR T-cell therapy. The study will also look at how the uptake of 89Zr-atezolizumab relates to the effectiveness of the CAR T-cell therapy and any side effects that may occur. This research hopes to provide insights into the role of PD-L1 in DLBCL and improve understanding of how patients respond to CAR T-cell therapy.
The Netherlands 
